Literature DB >> 27268395

Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease?

Karlynn E Neu1, Carole J Henry Dunand2, Patrick C Wilson3.   

Abstract

Current seasonal influenza virus vaccines are effective against infection but they have to be reformulated on a regular basis to counter antigenic variations. The majority of the antibodies induced in response to seasonal vaccination are strain-specific. However, antibodies targeting conserved epitopes on the hemagglutinin protein have been identified and they offer broad protection. Most of these antibodies bind the hemagglutinin stalk domain and are generated from preexisting memory B cells. Broadly protective stalk-biased responses induced by antigenically divergent influenza strains, in concert with prior immunity, are sufficient to eradicate seasonally circulating strains. Future vaccine trials should aim to harness and maintain such a response with the realistic goal of developing a universal influenza vaccine.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27268395      PMCID: PMC5086271          DOI: 10.1016/j.coi.2016.05.012

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  87 in total

1.  The Quest for a Universal Flu Vaccine: Headless HA 2.0.

Authors:  Florian Krammer
Journal:  Cell Host Microbe       Date:  2015-10-14       Impact factor: 21.023

Review 2.  Adaptive pathways of zoonotic influenza viruses: from exposure to establishment in humans.

Authors:  Leslie A Reperant; Thijs Kuiken; Albert D M E Osterhaus
Journal:  Vaccine       Date:  2012-04-24       Impact factor: 3.641

Review 3.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

4.  A common solution to group 2 influenza virus neutralization.

Authors:  Robert H E Friesen; Peter S Lee; Esther J M Stoop; Ryan M B Hoffman; Damian C Ekiert; Gira Bhabha; Wenli Yu; Jarek Juraszek; Wouter Koudstaal; Mandy Jongeneelen; Hans J W M Korse; Carla Ophorst; Els C M Brinkman-van der Linden; Mark Throsby; Mark J Kwakkenbos; Arjen Q Bakker; Tim Beaumont; Hergen Spits; Ted Kwaks; Ronald Vogels; Andrew B Ward; Jaap Goudsmit; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-11       Impact factor: 11.205

5.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

6.  Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.

Authors:  Ha T Nguyen; Tiffany G Sheu; Vasiliy P Mishin; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

7.  A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin.

Authors:  Jens C Krause; Tshidi Tsibane; Terrence M Tumpey; Chelsey J Huffman; Christopher F Basler; James E Crowe
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

8.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

9.  Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.

Authors:  Matthew S Miller; Thomas J Gardner; Florian Krammer; Lauren C Aguado; Domenico Tortorella; Christopher F Basler; Peter Palese
Journal:  Sci Transl Med       Date:  2013-08-14       Impact factor: 17.956

Review 10.  Influenza virus hemagglutinin stalk-based antibodies and vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Curr Opin Virol       Date:  2013-08-24       Impact factor: 7.090

View more
  45 in total

1.  Hemagglutinin Stalk-Reactive Antibodies Interfere with Influenza Virus Neuraminidase Activity by Steric Hindrance.

Authors:  Yao-Qing Chen; Linda Yu-Ling Lan; Min Huang; Carole Henry; Patrick C Wilson
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.

Authors:  Rong Deng; Ai Ping Lee; Mauricio Maia; Jeremy J Lim; Tracy Burgess; Priscilla Horn; Michael A Derby; Elizabeth Newton; Jorge A Tavel; William D Hanley
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

3.  Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection.

Authors:  Zhaochen Luo; Alanson W Girton; Brook E Heaton; Nicholas S Heaton
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

Review 4.  What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Lessons from the Antibody Response to HIV-1.

Authors:  Gabriel D Victora; Hugo Mouquet
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

Review 5.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

6.  Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.

Authors:  Ki-Hye Kim; Yu-Jin Jung; Youri Lee; Bo Ryoung Park; Judy Oh; Yu-Na Lee; Min-Chul Kim; Subbiah Jeeva; Sang-Moo Kang
Journal:  Virology       Date:  2020-08-22       Impact factor: 3.616

7.  Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.

Authors:  Ericka Kirkpatrick; Carole Henry; Meagan McMahon; Kaijun Jiang; Shirin Strohmeier; Harm van Bakel; Patrick C Wilson; Florian Krammer
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

8.  Protein Vaccination Directs the CD4+ T Cell Response toward Shared Protective Epitopes That Can Be Recalled after Influenza Virus Infection.

Authors:  Ajitanuj Rattan; Katherine A Richards; Zackery A G Knowlden; Andrea J Sant
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

9.  Effect of Priming With Seasonal Influenza A(H3N2) Virus on the Prevalence of Cross-Reactive Hemagglutination-Inhibition Antibodies to Swine-Origin A(H3N2) Variants.

Authors:  Feng Liu; Vic Veguilla; F Liaini Gross; Eric Gillis; Thomas Rowe; Xiyan Xu; Terrence M Tumpey; Jacqueline M Katz; Min Z Levine; Xiuhua Lu
Journal:  J Infect Dis       Date:  2017-09-15       Impact factor: 5.226

10.  Hide and seek: interplay between influenza viruses and B cells.

Authors:  Masayuki Kuraoka; Yu Adachi; Yoshimasa Takahashi
Journal:  Int Immunol       Date:  2020-09-08       Impact factor: 4.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.